Revolution Medicines/$RVMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Ticker
$RVMD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
616
ISIN
US76155X1000
Website
RVMD Metrics
BasicAdvanced
$7.4B
-
-$4.02
1.11
-
Price and volume
Market cap
$7.4B
Beta
1.11
52-week high
$60.59
52-week low
$29.17
Average daily volume
1.8M
Financial strength
Current ratio
13.459
Quick ratio
13.258
Long term debt to equity
5.84
Total debt to equity
6.464
Profitability
EBITDA (TTM)
-782.745
Effective tax rate (TTM)
0.11%
Management effectiveness
Return on assets (TTM)
-23.09%
Return on equity (TTM)
-36.68%
Valuation
Price to book
3.58
Price to tangible book (TTM)
3.71
Price to free cash flow (TTM)
-11.52
Free cash flow yield (TTM)
-8.68%
Free cash flow per share (TTM)
-346.63%
Growth
Earnings per share change (TTM)
8.38%
3-year earnings per share growth (CAGR)
12.60%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Bulls say / Bears say
Revolution Medicines' RAS(ON) inhibitor, zoldonrasib, demonstrated a 61% objective response rate and an 89% disease control rate in non-small cell lung cancer patients at 1200 mg QD, indicating strong clinical efficacy. (stockanalysis.com)
The company successfully closed an upsized public offering, raising $862.5 million, which strengthens its financial position to advance its oncology pipeline. (barchart.com)
Analysts maintain a 'Strong Buy' consensus with a 12-month average price target of $68.75, suggesting a potential upside of approximately 70%. (stockanalysis.com)
Shares of Revolution Medicines dropped approximately 31% pre-market after presenting data from Phase 1/1b studies for its RAS(ON) inhibitor RMC-6236, raising concerns about the drug's market reception. (seekingalpha.com)
Insider selling activity, including CFO Jack Anders selling 2,635 shares, may signal potential concerns about the company's near-term prospects. (techdows.com)
Despite positive analyst ratings, the stock has experienced volatility, with a notable decline of 7% over a four-week period, indicating potential market skepticism. (wallstrank.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
RVMD News
AllArticlesVideos
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
GlobeNewsWire·1 month ago
Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress
GlobeNewsWire·1 month ago
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Revolution Medicines stock?
Revolution Medicines (RVMD) has a market cap of $7.4B as of June 20, 2025.
What is the P/E ratio for Revolution Medicines stock?
The price to earnings (P/E) ratio for Revolution Medicines (RVMD) stock is 0 as of June 20, 2025.
Does Revolution Medicines stock pay dividends?
No, Revolution Medicines (RVMD) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Revolution Medicines dividend payment date?
Revolution Medicines (RVMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Revolution Medicines?
Revolution Medicines (RVMD) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.